Understanding host immune responses in Clostridioides difficile infection: Implications for pathogenesis and immunotherapy

IF 23.7 Q1 MICROBIOLOGY
iMeta Pub Date : 2024-05-11 DOI:10.1002/imt2.200
Lamei Wang, Javier A. Villafuerte Gálvez, Christina Lee, Shengru Wu, Ciaran P. Kelly, Xinhua Chen, Yangchun Cao
{"title":"Understanding host immune responses in Clostridioides difficile infection: Implications for pathogenesis and immunotherapy","authors":"Lamei Wang,&nbsp;Javier A. Villafuerte Gálvez,&nbsp;Christina Lee,&nbsp;Shengru Wu,&nbsp;Ciaran P. Kelly,&nbsp;Xinhua Chen,&nbsp;Yangchun Cao","doi":"10.1002/imt2.200","DOIUrl":null,"url":null,"abstract":"<p><i>Clostridioides difficile</i> (<i>C. difficile</i>) is the predominant causative agent of nosocomial diarrhea worldwide. Infection with <i>C. difficile</i> occurs due to the secretion of large glycosylating toxin proteins, which can lead to toxic megacolon or mortality in susceptible hosts. A critical aspect of <i>C. difficile's</i> biology is its ability to persist asymptomatically within the human host. Individuals harboring asymptomatic colonization or experiencing a single episode of <i>C. difficile</i> infection (CDI) without recurrence exhibit heightened immune responses compared to symptomatic counterparts. The significance of these immune responses cannot be overstated, as they play critical roles in the development, progression, prognosis, and outcomes of CDI. Nonetheless, our current comprehension of the immune responses implicated in CDI remains limited. Therefore, further investigation is imperative to elucidate their underlying mechanisms. This review explores recent advancements in comprehending CDI pathogenesis and how the host immune system response influences disease progression and severity, aiming to enhance our capacity to develop immunotherapy-based treatments for CDI.</p>","PeriodicalId":73342,"journal":{"name":"iMeta","volume":null,"pages":null},"PeriodicalIF":23.7000,"publicationDate":"2024-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/imt2.200","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"iMeta","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/imt2.200","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Clostridioides difficile (C. difficile) is the predominant causative agent of nosocomial diarrhea worldwide. Infection with C. difficile occurs due to the secretion of large glycosylating toxin proteins, which can lead to toxic megacolon or mortality in susceptible hosts. A critical aspect of C. difficile's biology is its ability to persist asymptomatically within the human host. Individuals harboring asymptomatic colonization or experiencing a single episode of C. difficile infection (CDI) without recurrence exhibit heightened immune responses compared to symptomatic counterparts. The significance of these immune responses cannot be overstated, as they play critical roles in the development, progression, prognosis, and outcomes of CDI. Nonetheless, our current comprehension of the immune responses implicated in CDI remains limited. Therefore, further investigation is imperative to elucidate their underlying mechanisms. This review explores recent advancements in comprehending CDI pathogenesis and how the host immune system response influences disease progression and severity, aiming to enhance our capacity to develop immunotherapy-based treatments for CDI.

Abstract Image

了解艰难梭菌感染中的宿主免疫反应:发病机制和免疫疗法的意义
艰难梭状芽孢杆菌(C. difficile)是全球医院内腹泻的主要致病菌。感染艰难梭菌后会分泌大量糖基化毒素蛋白,可导致中毒性巨结肠或易感宿主死亡。艰难梭菌生物学特性的一个重要方面是它能在人类宿主体内无症状地存活。与有症状的人相比,无症状定植或经历过一次艰难梭菌感染(CDI)而未复发的人表现出更强的免疫反应。这些免疫反应的重要性怎么强调都不为过,因为它们在 CDI 的发生、发展、预后和结局中起着至关重要的作用。然而,我们目前对与 CDI 有关的免疫反应的了解仍然有限。因此,进一步研究以阐明其潜在机制势在必行。本综述探讨了在理解 CDI 发病机制以及宿主免疫系统反应如何影响疾病进展和严重程度方面的最新进展,旨在提高我们开发基于免疫疗法的 CDI 治疗方法的能力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
10.80
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信